Efficacy of new Albendazole formulations in treating Trichinella spiralis infected mice

GARCÍA, A.; BARRERA M.G; VASCONI, M.D.; DI MASSO, R.J.; HINRICHSEN, L; LEONARDI, D.; LAMAS M.C.

Rosario

Congreso; II Reunion Internacional de Ciencias Farmacéuticas (RICIFA); 2012

Albendazole (ABZ) is a benzimidazole derivative with a broad spectrum of activity against intestinal and systemic parasitosis. However, ABZ is classified as class II/IV by the Biopharmaceutical Classification System (BCS) because it has a very poor aqueous solubility that limits oral absorption. As a consequence, the bioavailability is very low and erratic. Furthermore, this aqueous insolubility reduces the pharmaceutical alternatives for drug formulation and administration, especially for pediatric patients. The aim of this study was to determine whether a microparticle formulation system improved ABZ anthelmintic efficacy in vivo in a murine model of trichinellosis.